Introduction
During the last decade (2000-2010) acute (anaphylactic) transfusion reactions, haemolytic transfusion reactions, transfusiontransmitted bacterial infections (TTBI), transfusion-transmitted viral infections (TTVI) and transfusion-related acute lung injuries (TRALI) were identified as most serious transfusion-related risks [1] [2] [3] [4] .
Various risk minimisation measures have been discussed to reduce these adverse reactions, and like other European competent authorities, the Paul-Ehrlich-Institut (PEI) imposed binding regulations on this. During the last decade the German blood establishments implemented several specific safety measures, such as HCV and HIV NAT donor testing, donor screening for antibodies to hepatitis B core antigen (anti-HBc) as well as shelf life reduction of platelet concentrates (PC) to reduce serious bacterial infections as well as TRALI risk minimisation measures.
Due to multifactorial route causes, no measures were implemented to reduce the increasing number of transfusion-related allergic reactions up to now. Whereas TTBI and TRALI are more frequent and cause immediate serious and even life-threatening complication, TTVI are very rare events and may lead to less severe reactions. However, TTVI provoke still an enhanced public awareness, and a high safety standard is required; particularly for the prevention of transfusion-transmitted HIV infections.
To evaluate the impact of safety measures, the PEI compared reporting rates of defined transfusion-related reactions before and after implementation of safety measures.
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Summary
Background:
To assess the impact of safety measures, we compared reporting rates of transfusion-related reactions before and after the implementation of six measures in 1999, 2004, 2006, 2008 and 2009 . Methods: Reporting rates of transfusion-transmitted bacterial infection (TTBI), viral infection (TTVI) and immune-mediated transfusion-related acute lung injury (TRALI) were calculated on the basis of confirmed annual reports and distributed blood components. Results: The introduction of HCV NAT testing caused a significant reduction of HCV reporting rate from 1:0.6 to 1:83.16 million administered blood components (p < 0.0001), donor screening for antibodies to hepatitis B core antigen caused a reduction of HBV reporting rate from 1:2.90 to 1:10.70 million units (p = 0.0168). A significant reduction from 1:0.094 to 1:2.42 million fresh frozen plasma (FFP) units could also be achieved by risk minimisation TRALI measures (p < 0.0001). Implementation of pre-donation sampling did not result in a significant decrease in TTBI, whereas limitation of shelf life for platelet concentrate (PC) minimised the TTBI reporting rate from 1:0.088 to 1:0.19 million PC units (p = 0.041). For HIV NAT pool testing, no significant reduction in HIV transmission was found due to very low reporting rates (1:10 million versus 1:27 million blood components, p = 0.422). Conclusion: On the basis of haemovigilance data, a significant benefit could be demonstrated for four of six implemented safety measures.
Material and Methods
According to the German Medicinal Products Act (AMG Section 63) and the German Transfusion Act (TFG Section 16), blood establishments and treating physicians are obliged to report serious adverse reactions directly to the PEI within 15 days following their occurrence. Physicians are requested to provide any missing data such as main symptoms, clinical course and identification and categorisation of the pathogenic agent affecting the recipient as well as data of involved blood components. When a transfusion-related reaction is confirmed, further specific laboratory analysis of affected blood donors or involved blood components are usually requested.
The evaluation of a causal relationship for a suspected transfusion-related virus infection is based on the guidelines of the German Advisory Group Blood (Opinion 34). Causality assessment criteria include the categories: certain, probable, possible, unlikely and non-assessable [5] .
In cases of suspected transfusion-related bacterial infections, blood samples of affected recipients and samples of transfused products need to be analysed microbiologically using aerobic and anaerobic cultures. TTBI are defined by clinical criteria associated with a culture-positive residual component and a culture-positive recipient demonstrating the same bacteria as, for instance, determined by antibiotic sensitivity.
The diagnosis of TRALI is confirmed if the criteria of acute respiratory distress during or within 6 h of transfusion, radiographic evidence of (new) bilateral pulmonary infiltrates and absence of signs of circulatory overload were fulfilled (ISBT criteria) [6] . In addition, the blood donors concerned should be analysed for leucocyte antibodies in order to distinguish between immune and non-immune TRALI. Standardised analyses of HNA and HLA antibodies have been described since 2002 [7] .
Risk Minimisation Measures
A number of risk minimisation measures have been imposed by the PEI or have been recommended by the German Advisory Group Blood.
Since 1999, in addition to serological donor testing, HCV NAT testing (HCV RNA detection limit: 5,000 IU/ml) has been implemented to prevent further transfusion-related HCV infections. HIV NAT testing (HIV RNA detection limit: 10,000 IU/ml) has been requested since May 2004 as an additional blood donor screening measure. To reduce transfusion-related hepatitis B infections, screening of blood donors with an anti-HBc test was implemented in October 2006.
Regarding transfusion-related bacterial infections, the German Advisory Committee Blood recommended risk minimisation measures in 2002 and 2008. These implementations occurred on a voluntary basis by the blood donation establishments. To achieve a reduction in microbial contamination of blood components, pre-donation sampling has been recommended since June 2003 (German Advisory Group Blood, Opinion 27). This includes the separation and removal of at least 15 ml after venepuncture before harvesting donors' blood. Since June 2008, a limitation of the shelf life of PC has been recommended (German Advisory Group Blood, Opinion 38). In 2008 it was recommended to limit the storage of PC to 4 days (4 × 24 h); beginning at midnight of the day the blood was collected to reduce the danger of serious or fatal bacterial infections.
Combined measures were implemented in September 2009 to reduce the reporting rate of immune-mediated TRALI. Female donors with a history of pregnancy should be excluded from fresh frozen plasma (FFP) donation. Female donors with a history of pregnancy could be accepted when tested negative for HLA class I, HLA class II, HNA 1a, HNA 1b, HNA-2 and HNA-3a antibodies.
The reporting rate of defined transfusion-related reactions was calculated on the basis of reactions fulfilling consensus criteria and the number of transfused blood components. The figures of transfused FFP, PC and red blood cells (RBC) must be reported to the PEI annually according to Section 21 of the German Transfusion Act.
Statistical Analysis
The reporting rates before and after the implementation of each risk minimisation measure were compared by means of a 2-sample Poisson test, with two-sided p values < 0.05 indicating statistically relevant differences. Reporting rate ratios (RRR) including their 95% confidence intervals (95% CI) were used to describe the corresponding effects (RRR < 1 indicating an effect of the intervention). R, version 3.02, was used for statistical analysis [8] . 
Results
Reporting Rates of TTVI (HBV/HCV/HIV)
A total of 106 million blood components were distributed by the German blood establishments within a period of 17 years (1997-2013) , and approximately 101 million units were transfused: 71.51 million RBC concentrates 22.05 million FFP and 6.70 million PC as shown in table 1.
During the whole haemovigilance period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) , an overall amount of 3,322 suspected cases of transfusion-associated virus infections were reported to the PEI: 1,902 HCV, 188 HIV and 1,232 possible HBV cases. According to Opinion 34 regarding look-back procedures (German Advisory Group Blood) and according to published operational procedure [5] , only 50 out of 3,322 notifications (1.5%) have been confirmed.
19 HCV transmissions were confirmed before the implementation of HCV NAT testing during a 2-year period (1997 and 1998). On the basis of 11.40 million transfused blood components this corresponds to a reporting frequency of 1.67 cases per million units (table 2) . After the implementation in 1999 over a period of 14 years and an equivalent of 83.16 million transfused blood components, only one further HCV transmission was reported, corresponding to a highly significant difference (RRR 0.006, 95% CI 0.0002-0.0461; p < 0.0001).
Prior to the implementation of HIV NAT testing during a period of 7 years (1997-2003), four HIV transmissions were confirmed. This corresponds to 0.1 cases per million units (40.31 million transfused blood components). After the implementation in 2004, two further HIV transmissions occurred over a period of 9 years and an equivalent of 54.47 transfused blood components ( 
Discussion
In evaluating the reduction of transfusion-related reactions, various factors must be considered that may influence reporting rates. The German Haemovigilance System as defined by the Medicinal Products Act came into force in 1997. No sufficient data are available for statistical analysis before that date. It is also obvious that reporting rates do not provide a complete picture of the frequency of transfusion reactions and therefore are not comparable with study data.
HCV On the basis of the German haemovigilance data, a significant reduction in HCV transmission could be confirmed after the introduction of HCV NAT testing. Regarding HBV transmission, the introduction of anti-HBc donor testing reduced the reporting rate to one third by an average of 1 transmission per year. To achieve this reduction, a high rate of unspecific positive test results and consequently a high number of donor-related look-back procedures have to be accepted. Because of the occurrence of two HIV transmissions in 2007 and 2010, no significant benefit was demonstrated for HIV NAT testing. In both cases with HIV-1 RNA falsenegative test results nucleotide sequencing of the viral target region revealed new HIV-1 variants that mismatched with primers of mono-target assays. It could be assumed that dual-target assays would have been capable to detect new variants to a large extent. A prevention of these cases would have led to a measurable improvement, but on the basis of two HIV transmissions a period of 17 years (2005-2022) is needed to prove a significant difference. Therefore, the effect HIV NAT testing has to be discussed considering the low overall reporting rate of transfusion-related HIV infection. In addition to these reporting data, the rate of NAT-onlypositive donations following introduction of NAT testing demonstrate that NAT testing considerably contributed to a risk minimisation regarding TTVI [9] .
Other haemovigilance systems demonstrate comparable reporting rates. The Swissmedic haemovigilance report 2013 describes only single cases of TTVI in the last decade with currently estimated risks of 1: 6.7 million donations for HCV, 1: 4.1 million donations for HIV and 1: 1.4 million donations for HBV [2] . According to the SHOT report 2013, only one single HCV and HIV transmission, but 10 HBV transmissions have been confirmed for blood components in the UK since 1997 [1] . Data of the SHOT report lead to the assumption that one potentially infectious HIV transmission could be expected every 3 years due to negative serological test results during the window period [1] . It was also stated that far fewer HIV transmissions are observed in practice, partly because the estimate has wide uncertainty and the model does not incorporate pack non-use and recipient susceptibility to infection. Also under-ascertainment and underreporting has to be considered, for example due to recipients dying from an underlying medical condition before a chronic asymptomatic viral condition is identified, or, in the case of HBV, an asymptomatic acute infection.
Regarding TTBI, a minimal reduction of TTBI reporting rate from 13.8 to 11.4 cases per million PC was seen after the introduction of pre-donation sampling. The implementation of the shelf life reduction halved the reporting rate further to 5.3 per million units, corresponding with one TTBI case in 190,000 platelet units. A significant decrease in the reporting rate could only be demonstrated 5 years after implementation.
TTBI data of other haemovigilance systems are partly consistent with our data. The SHOT report 2009 confirmed a total of 22 TTBIs during the last 10 years, representing a reporting frequency of 1 case in 117,000 platelet units [1] . After the implementation of bacterial screening testing, no further TTBIs have been confirmed since 2009 as described in the UK (SHOT report 2013) [1] . In contrast, despite bacterial screening testing, the American Red Cross (ARC) published TTBI frequencies between 1: 40,000 and 1: 193,000 depending on the collecting procedure. The fatality rate was one in 500,000 platelet units [10] . Swissmedic described an estimated TTBI risk of 1: 600,000 donations for the last decade [2] ; after the introduction of pathogen inactivation procedure for all PC (2011), no further TTBI was confirmed [11] .
To interpret the benefit of risk-reducing measures, the multifactorial aetiology of TTBI must be considered as already described [12] . The removal of the initial 10-40 ml of blood after venepuncture before drawing donors' blood has been shown to reduce the bacterial load introduced into manufactured blood components by 40-90% although no significant effect was demonstrated [13] . A comparable evaluation in Germany revealed a significant reduction of bacterial contamination compared to periods without pre-donation sampling for RBC concentrates and pooled PC [14] , demonstrating that this measure is effective in reducing contamination of blood components with skin bacteria at the time of phlebotomy. On the other hand, limitations of the PC shelf life focus on the prevention of severe bacterial infections due to a high bacterial level after a longer incubation time, caused by unrecognised donor bacteraemia or insufficient skin disinfection, but will not be suitable to avoid infections with skin bacteria in immunosuppressed patients.
Additional measures may lead to a further decrease of TTBI. These could be more effective and reliable screening tests or adequate pathogen reduction procedures. To balance the benefits, risks and burden of these strategies, more data as well as scientific evaluations are needed [11, 15, 16] . After the exclusion of female donors with a history of pregnancy from FFP donation, only 2 immune-mediated TRALI that fulfilled consensus criteria during a 4-year period were reported. Since then, no TRALI case with fatal outcome was reported after FFP administration and 1 single case caused by a PC. Our data show that a significant reduction in immune-mediated TRALI was achieved by a defined risk minimisation measure. The testing of female donors also provides the opportunity to exclude only subjects with an increased risk and maintain for example important apheresis donors. This is in accordance with haemovigilance data of the SHOT report. In 2003, the English National Blood Services introduced a 'male only plasma policy', which covers all high plasma components [3] . After the implementation of the safety measure, the overall risk of confirmed TRALI fell from 15. [17] . In the USA, the ARC implemented a 'male-predominant plasma strategy' comparable to the measures in the UK and Canada [18, 19] . Since November 2007, plasma collection for FFP was restricted to male-only donors, whereas platelet donations were not included. After the implementation of safety measures, the ARC demonstrated a decrease in 80% for TRALI cases involving only plasma transfusion (19.5 vs. 4.0 per million) and a reduction from 6 fatal cases in 2006 to zero in 2008 [20] .
Since 2010, we confirmed 10 immune-mediated TRALI cases after administration of RBC concentrates (6 cases) and PC (4 cases). In accordance with the ISBT criteria, also 4 non-immunemediated TRALI were seen. Based on these cases, the extension of TRALI safety measures has been discussed, but at present, the number of cases fulfilling consensus criteria is too limited to justify further steps.
On basis of current haemovigilance data we can conclude that serious transfusion-related reactions are rare complications. After implementation of risk minimisation measures, a low reporting rate was demonstrated for TTBI (1: 0.19 million) and very low rates for immune-mediated TRALI (1: 2.42 million) and TTVI (<1: 10 million). Reporting rates for transfusion-related fatalities ranged between 1: 1.23 million for TTBI and no reported case for immunemediated TRALI. In comparison risk minimisation measures like introduction of safety standards and improved training resulted in a decrease of anaesthesia-related mortality from 6.4: 10,000 in the 1940s to 0.4: 100,000 at present [21] .
In four of six implemented safety measures a significant benefit could be demonstrated on the basis of haemovigilance data. Although haemovigilance data showed little benefit of pre-donation sampling, a significant reduction of bacterial contamination for RBC concentrates and pooled PC was observed [14] . Also the effect of HIV NAT testing has to be considered as limited because of the very low reporting rates (1: 10 million vs. 1: 27 million units).
Risk minimisation measures should only be implemented on the basis of a careful risk analysis. The introduction of defined and product-specific measures allows an ongoing evaluation of risk reduction and, if necessary, a modification of initial measures.
